Skip to main content
. 2024 Nov 15;10(23):e40404. doi: 10.1016/j.heliyon.2024.e40404

Fig. 1.

Fig. 1

(A) The ribbon and surface representation of the SARS-CoV-2 3CLpro (PDB ID: 7L13) with the inhibitor-bound active site; (B) the active site of SARS-CoV-2 3CLpro (PDB ID: 7L13) along with sub-sites; (C) non-covalent inhibitor-bound SARS-CoV-2 3CLpro (PDB ID: 7L13) active site with important sub-sites.